المؤلفون: Frederick L, Locke, David B, Miklos, Caron A, Jacobson, Miguel-Angel, Perales, Marie-José, Kersten, Olalekan O, Oluwole, Armin, Ghobadi, Aaron P, Rapoport, Joseph, McGuirk, John M, Pagel, Javier, Muñoz, Umar, Farooq, Tom, van Meerten, Patrick M, Reagan, Anna, Sureda, Ian W, Flinn, Peter, Vandenberghe, Kevin W, Song, Michael, Dickinson, Monique C, Minnema, Peter A, Riedell, Lori A, Leslie, Sridhar, Chaganti, Yin, Yang, Simone, Filosto, Jina, Shah, Marco, Schupp, Christina, To, Paul, Cheng, Leo I, Gordon, Jason R, Westin, Allen, Xue

المساهمون: Stem Cell Aging Leukemia and Lymphoma (SALL), Hematology, Clinical Haematology, AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life

المصدر: New England Journal of Medicine, 640-654. MASSACHUSETTS MEDICAL SOC
ISSUE=386;STARTPAGE=640;ENDPAGE=654;ISSN=0028-4793;TITLE=New England Journal of Medicine
The New England journal of medicine, 386(7), 640-654. Massachussetts Medical Society
New England journal of medicine, 386(7), 640-654. Massachussetts Medical Society
All ZUMA-7 Investigators and Contributing Kite Members 2022, ' Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma ', New England Journal of Medicine, vol. 386, no. 7, pp. 640-654 . https://doi.org/10.1056/NEJMoa2116133
New England Journal of Medicine, 386(7), 640-654. Massachussetts Medical Society

مصطلحات موضوعية: Adult, Aged, 80 and over, Male, SALVAGE REGIMENS, Biological Products, OUTCOMES, Receptors, Chimeric Antigen, TRANSPLANTATION, MULTICENTER, General Medicine, Middle Aged, CHEMOTHERAPY, Immunotherapy, Adoptive, Transplantation, Autologous, Progression-Free Survival, Antineoplastic Agents, Immunological, EVENT, Drug Resistance, Neoplasm, SURVIVAL, Humans, Female, Lymphoma, Large B-Cell, Diffuse, CHEMOIMMUNOTHERAPY, Aged, Stem Cell Transplantation

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2287074e9e3a4938b8881d67fc763d95
https://doi.org/10.1056/nejmoa2116133